Overall Status

Completed (20)

Withdrawn (3)

Active, not recruiting (2)

Terminated (2)

Phase

phase 2 (14)

phase 1 (4)

phase 3 (4)

phase 4 (3)

phase 1/phase 2 (1)

phase 2/phase 3 (1)

Collaborator

Novartis (5)

Novartis Pharmaceuticals (2)

Barts & The London NHS Trust (1)

Massachusetts General Hospital (1)

National Cancer Institute (NCI) (1)

Oxford University Hospitals NHS Trust (1)

The Christie NHS Foundation Trust (1)

Veterans Medical Research Foundation (1)

Study Documents

Intervention Type

drug (27)

other (1)

procedure (1)

Funder Type

Other (17)

Industry (10)

Study Type

Interventional (27)

pasireotide

Showing 26 - 27 of 27

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Symptomatic Refractory Resistant Carcinoid Disease Trial in Worldwide (Pasireotide, Octreotide)

Completed

Has Results

Symptomatic Refractory Resistant Carcinoid Disease

Pasireotide
Octreotide

Scottsdale, Arizona
+61 more

Jun 25, 2013

Multiple Myeloma Trial in Hershey (Pasireotide, Everolimus)

Withdrawn

Multiple Myeloma

Pasireotide
Everolimus

Hershey, Pennsylvania

Penn State Milton S. Hershey Medical Center

Jan 8, 2013